Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931528 · ClinicalTrials.gov registry record · Phase 3
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
A Phase 3 study of Prostate Cancer and Sexual Dysfunction, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
- 20
- Study locations
NCT00931528 is a Phase 3 study of Prostate Cancer and Sexual Dysfunction that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 242 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00931528, a Phase 3 study of Prostate Cancer and Sexual Dysfunction, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction. PURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tadalafil
Study Locations (20)
California
- Sutter Cancer Centers Radiation Oncology Services-Auburn - Auburn
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park - Cameron Park
- Mercy San Juan Medical Center - Carmichael
- Enloe Medical Center - Chico
- Saint Agnes Medical Center - Fresno
- Veterans Administration Long Beach Medical Center - Long Beach
- Northridge Hospital Medical Center - Northridge
- Kaiser Permanente Oakland-Broadway - Oakland
- Sutter Cancer Centers Radiation Oncology Services-Roseville - Roseville
- Radiological Associates of Sacramento - Sacramento
- Mercy General Hospital Radiation Oncology Center - Sacramento
- UCSF-Mount Zion - San Francisco
- California Pacific Medical Center - San Francisco
Arizona
- Arizona Center for Cancer Care-Peoria - Peoria
- Mayo Clinic in Arizona - Scottsdale
- Arizona Oncology Services Foundation - Scottsdale
- Arizona Oncology Associates-West Orange Grove - Tucson
Alabama
- University of Alabama at Birmingham - Birmingham
- Providence Hospital - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931528
The ClinicalTrials.gov registry entry for NCT00931528 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (60% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00931528 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00931528 about?
NCT00931528 is a clinical study titled "Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy". RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction. PURPOSE: This randomized phase III trial is study...
What is the current status of trial NCT00931528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2009-11. Estimated completion is 2014-11.
What conditions does trial NCT00931528 study?
This clinical trial studies the following conditions: Prostate Cancer, Sexual Dysfunction.
What interventions are being tested in trial NCT00931528?
The interventions under investigation include: Placebo (OTHER), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT00931528?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00931528 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.